Profil bibliographique

Laura Cortesi

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

14Publications signalées

32Citations signalées

2Affiliations récentes

Institutions déclarées

Azienda Unita' Sanitaria Locale Di Modena Azienda Ospedaliero-Universitaria di Modena

Domaines associés

BRCA gene mutations in cancerPARP inhibition in cancer therapyAdvanced Breast Cancer TherapiesBreast Cancer Treatment StudiesCancer Risks and Factors

Publications récentes

Accès ouvert 2026 article

Impaired glucose tolerance in women with BRCA1 versus BRCA2 pathogenic or likely pathogenic variants: Results from a prospective cohort study

Giovanni Grandi, Claudia Piombino, Giovanna Sighinolfi, Elena Barbieri et autres

0 citationsFamilial Cancer

Accès ouvert 2025 article

Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer

Emma Zattarin, Antonio Marra, Antonella Palazzo, Gaia Griguolo et autres

5 citationsnpj Breast Cancer

Accès ouvert 2025 article

A RANDOMIZED PHASE III STUDY OF FIRST-LINE SARUPARIB (AZD5305) + CAMIZESTRANT VS CDK4/6I + PHYSICIAN’S CHOICE ENDOCRINE THERAPY OR CDK4/6I + CAMIZESTRANT IN PTS WITH HR+/HER2- ADVANCED BREAST CANCER WITH BRCA1/ BRCA2/PALB2 MUTATIONS (EVOPAR-BREAST01)

Alexandra Mesquita, Pedram Razavi, Judith Balmañà, Stephen J. Luen et autres

0 citationsThe Breast

Accès ouvert 2025 article

The use of hormonal contraceptives in a cohort of healthy women with BRCA mutations under surveillance in an Italian Family Cancer Clinic

Giovanni Grandi, Alice Sgandurra, Lia Feliciello, Gloria Guariglia et autres

1 citationThe European Journal of Contraception & Reproductive Health Care

2025 conference-abstract

Abstract P2-10-17: A randomized phase III study of first-line saruparib (AZD5305) + camizestrant vs CDK4/6i plus physician’s choice endocrine therapy or + camizestrant in patients w/ BRCA1/BRCA2/PALB2 mutations & HR+/HER2- advanced breast cancer (EvoPAR-Breast01)

Pedram Razavi, Judith Balmaña, Stephen J. Luen, Mario Campone et autres

4 citationsClinical Cancer Research

2025 conference-abstract

Abstract P2-10-23: ASSESSING CLINICAL FEATURES AND OUTCOME OF BREAST CANCER IN PALB2 MUTATION CARRIERS: AN EUROPEAN MULTICENTRIC RETROSPECTIVE HOSPITAL-BASED COHORT CONTROL STUDY (PALBREAST)

Laura Cortesi, Benedetta Pellegrino, Federica Caggia, Martina Manni et autres

0 citationsClinical Cancer Research

2025 conference-abstract

PARPi effectiveness after CDK4/6i in BRCA1 - and BRCA2 -associated HR+/HER2- advanced breast cancer: Results from the multicenter real-world PAMBRACA study.

Emma Zattarin, Antonio Marra, Antonella Palazzo, Gaia Griguolo et autres

2 citationsJournal of Clinical Oncology

Accès ouvert 2025 article

Advancing breast cancer therapy in the era of molecular diagnostics

Maria Grazia Carnevale, Riccardo Ray Colciago, Maria Carmen De Santis, Laura Cortesi et autres

10 citationsThe Breast

Accès ouvert 2025 article

Reduced reproductive potential in young healthy women with hereditary breast and/or ovarian cancer syndrome

Giovanna Sighinolfi, Giovanni Grandi, Elena Barbieri, Marta Venturelli et autres

5 citationsCommunications Medicine

Accès ouvert 2024 article

Chemoprevention strategies in hereditary breast and ovarian cancer syndromes

Elena Barbieri, Marta Venturelli, Luciana Mastrodomenico, Claudia Piombino et autres

3 citationsTumori Journal

Accès ouvert 2024 article

Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project

Stefania Gori, Fiorenza De Rose, Antonella Ferro, Alessandra Fabi et autres

2 citationsCancer Treatment Reviews

Accès ouvert 2024 preprint

Contralateral Prophylactic Mastectomy and Oophorectomy Increase the Survival in Brca-Related Breast Cancer: The Italian Mutina Study

Laura Cortesi, Giulia Cortesi, Marta Venturelli, Angela Toss et autres

0 citationsSSRN Electronic Journal

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Métadonnées interrogées à la demande auprès de OpenAlex (CC0). Sources et limites.